Is JNJ a good stock to buy? We came across a bullish thesis on Johnson & Johnson on Dividend School’s Substack by School of Investing. In this article, we will summarize the bulls’ thesis on JNJ. Johnson & Johnson’s share was trading at $237.00 as of June 9th. JNJ’s trailing and forward P/E were 26.97 and 20.12 respectively according to Yahoo Finance.
Photo by Ani Kolleshi on Unsplash
Johnson & Johnson (JNJ) is presented as one of the highest-quality dividend paying businesses, combining defensive healthcare exposure with exceptional financial strength and a long history of shareholder returns. The company operates through Innovative Medicine and MedTech following separation of its consumer health division, focusing on patented pharmaceuticals and high-margin medical devices that benefit from strong switching costs and regulatory barriers.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
In 2024, JNJ generated $88.8 billion in revenue with operational growth of 5.9%, supported by heavy reinvestment of nearly $17 billion, or 19.4% of sales, into research and development to sustain its future pipeline. Despite this investment intensity, the company maintains a robust profitability profile and produced $20 billion in free cash flow, supporting both reinvestment and shareholder distributions. JNJ’s dividend profile stands out with a conservative payout ratio near 46%, providing substantial coverage and flexibility for continued increases even during downturns.
Its balance sheet strengthens the investment case, supported by a AAA credit rating, $25 billion in cash and marketable securities, and manageable debt levels of approximately $37 billion, allowing rapid deleveraging potential from cash flow generation. The company has increased its dividend for 63 consecutive years, underscoring durability through multiple economic cycles.
While patent expirations as Stelara present near-term pressure, JNJ’s diversified pipeline, scale advantages, and acquisition-driven expansion of Innovative Medicine portfolio support long-term growth resilience. Overall Johnson & Johnson represents a high-quality compounder with defensive earnings, best-in-class balance sheet strength, and a well-covered dividend that positions it as a core long-term income and capital preservation holding.
Previously, we covered a bullish thesis on Johnson & Johnson (JNJ) by The Antifragile Investor in January 2025, which highlighted its shift toward Innovative Medicine and MedTech, supported by strong oncology growth, biologics strength, and global healthcare exposure. JNJ’s stock price has appreciated by approximately 62.07% since our coverage. School of Investing shares a similar view but emphasizes dividend durability, AAA balance sheet strength, and long-term income compounding potential.
Johnson & Johnson is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 113 hedge fund portfolios held JNJ at the end of the first quarter which was 104 in the previous quarter. While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
